- Home
- LVLU vs BIVI Comparison
LVLU vs BIVI Comparison
Compare LVLU & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- BIVI
- Stock Information
- Founded
- LVLU 1996
- BIVI 2013
- Country
- LVLU United States
- BIVI United States
- Employees
- LVLU N/A
- BIVI N/A
- Industry
- LVLU Catalog/Specialty Distribution
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- BIVI Health Care
- Exchange
- LVLU Nasdaq
- BIVI Nasdaq
- Market Cap
- LVLU 18.4M
- BIVI 18.6M
- IPO Year
- LVLU 2021
- BIVI N/A
- Fundamental
- Price
- LVLU $4.66
- BIVI $7.95
- Analyst Decision
- LVLU Hold
- BIVI
- Analyst Count
- LVLU 2
- BIVI 0
- Target Price
- LVLU $1.00
- BIVI N/A
- AVG Volume (30 Days)
- LVLU 782.4K
- BIVI 214.2K
- Earning Date
- LVLU 08-13-2025
- BIVI 05-12-2025
- Dividend Yield
- LVLU N/A
- BIVI N/A
- EPS Growth
- LVLU N/A
- BIVI N/A
- EPS
- LVLU N/A
- BIVI N/A
- Revenue
- LVLU $302,783,000.00
- BIVI N/A
- Revenue This Year
- LVLU N/A
- BIVI N/A
- Revenue Next Year
- LVLU $2.53
- BIVI N/A
- P/E Ratio
- LVLU N/A
- BIVI N/A
- Revenue Growth
- LVLU N/A
- BIVI N/A
- 52 Week Low
- LVLU $0.22
- BIVI $0.62
- 52 Week High
- LVLU $5.25
- BIVI $9.56
- Technical
- Relative Strength Index (RSI)
- LVLU 41.76
- BIVI 31.70
- Support Level
- LVLU $3.30
- BIVI $6.78
- Resistance Level
- LVLU $5.43
- BIVI $10.30
- Average True Range (ATR)
- LVLU 1.44
- BIVI 0.89
- MACD
- LVLU -0.13
- BIVI -0.27
- Stochastic Oscillator
- LVLU 26.59
- BIVI 27.08
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.